PGE Synthase

SC-19220 is a competitive antagonist of the prostaglandin E2 receptor, demonstrating significant effects on bladder physiology. Research indicates that SC-19220 enhances bladder capacity while decreasing voiding efficiency in urethane-anesthetized rats during slow transvesical filling. Additionally, SC-19220 has been shown to restore the balance of granulocyte and monocyte production in bone marrow following burn sepsis, making it a valuable tool for investigations related to inflammatory responses and urinary tract function.

Canniprene is a potent inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase/microsomal prostaglandin E2 synthase (PGE2), with IC50 values of 0.4 μM and 10 μM, respectively. Derived from Cannabis sativa, Canniprene modifies the biosynthesis of inflammatory eicosanoids and prostaglandins, making it a valuable tool for researching inflammation and related pathways. Its unique mechanism of action positions Canniprene as a potential candidate for studying inflammatory diseases and therapeutic interventions targeting lipid mediators.

Saikogenin D is an effective PGE2 inhibitor isolated from Bupleurum chinense. This compound exhibits significant anti-inflammatory properties by activating epoxygenases, leading to the conversion of arachidonic acid into epoxyeicosanoids and dihydroxyeicosatrienoic acids, which subsequently suppress PGE2 production. Saikogenin D also induces an increase in intracellular calcium levels ([Ca2+]i) through the release of Ca2+ from intracellular stores, making it a valuable tool for studying inflammatory pathways.

SC 34301, an orally active PGE1 analogue, exhibits potent anti-inflammatory properties. It has been shown to significantly reduce bacterial translocation and enhance survival rates in burned mouse models. This compound is valuable for research applications focusing on inflammation, tissue repair, and the physiological effects of prostaglandin analogues.

Prostaglandin E2 Ethanolamide (PGE2-EA) is a biologically active analog of Prostaglandin E2, chiefly targeting the modulation of inflammatory responses. It is formed enzymatically through the COX-2-mediated oxygenation of endocannabinoids. PGE2-EA demonstrates the ability to influence the production of the pro-inflammatory cytokine TNF-α in human blood and monocytic cells, making it a valuable tool for research in inflammation and immunology.

(+)-Oxypeucedanin methanolate is a potent inhibitor of prostaglandin E2 (PGE2) synthesis. This natural compound exhibits significant anti-inflammatory properties, making it a valuable reagent in studies focused on inflammation and pain modulation. Research applications include investigating the pathways of prostaglandin synthesis and exploring potential therapeutic interventions for inflammatory diseases.

ent-Prostaglandin E2 (ent-PGE2) is an enantiomer of Prostaglandin E2 that serves as a poor substrate for 15-hydroxyprostaglandin dehydrogenase. This differential substrate activity can be leveraged in various biochemical studies to investigate the enzymatic pathways and regulatory mechanisms involving prostaglandins. Research applications include studying the physiological effects of PGE2 and the role of its enantiomers in inflammatory processes and cell signaling pathways.

Tetranor-Prostaglandin E1 is a metabolite of Prostaglandin E1, resulting from β-oxidation processes. This compound serves as a crucial biomarker in studies related to prostaglandin metabolism and pathways. It is commonly utilized in research involving inflammatory responses and various physiological processes mediated by prostaglandins.

Prostaglandin E2 isopropyl ester serves as a precursor for Prostaglandin E2 (PGE2). This compound is instrumental in various biological processes, including inflammation and modulation of immune responses. Researchers commonly utilize it in studies focused on prostaglandin synthesis and signaling pathways related to pain, edema, and cellular growth. Its role in mediating physiological functions makes it a valuable reagent for elucidating mechanisms in both basic and applied biomedical research.

SC-42867 is a potent PGE2 antagonist, specifically designed to inhibit prostaglandin E2 signaling pathways. This compound is metabolized in the liver through mechanisms such as oxidative N-dealkylation and aromatic hydroxylation. SC-42867 is highly relevant for studies focused on metabolic conditions, allowing researchers to explore the biochemical implications of PGE2 modulation in various physiological processes.

FCE 20700 is an orally active analogue of prostaglandin E2 (PGE2) that primarily targets gastric mucosal integrity. It demonstrates the ability to prevent gastric mucosal damage and inhibit both gastric acid and pepsin secretion. This compound is valuable for research into gastrointestinal ulcers and related disorders, providing insights into therapeutic strategies for gastrointestinal protection.

Salviifoside A is a phenolic glycoside that acts as an inhibitor of nitric oxide (NO) and prostaglandin E2 (PGE2) production. Isolated from the leaves of Alangium salviifolium, Salviifoside A effectively suppresses LPS-induced nitric oxide and prostaglandin E2 production in macrophages while maintaining cell viability. This compound is valuable for research focused on inflammatory responses and the modulation of macrophage activation.

13,14-Dihydro-15-keto-tetranor prostaglandin E2 is a novel metabolite of Prostaglandin E2, functioning primarily as a bioactive mediator in various physiological processes. As a key derivative, it is involved in studies exploring the metabolic pathways of prostaglandins and their implications in inflammation and other biological responses. This compound has significant applications in research focused on prostaglandin signaling and its role in disease mechanisms.

8-Iso-16-cyclohexyl-tetranor prostaglandin E2 is a PGE2 analog that exhibits potent biological activity by modulating various physiological processes. It engages the prostaglandin receptors, influencing pathways related to inflammation, pain, and vascular regulation. This compound is valuable for research applications focused on the roles of prostaglandins in disease models, as well as studies investigating receptor-targeted therapies.

15-Methylprostaglandin E1 is an analog of prostaglandin E1 (PGE1) that primarily targets prostaglandin receptors to elicit cardiovascular effects. It demonstrates a positive chronotropic effect, leading to increased heart rate and enhanced levels of nicardipine. This compound is widely utilized in studies related to circulatory system regulation and pharmacological investigations into heart rate modulation.

(15S)-15-Methylprostaglandin E2 is a synthetic analog of prostaglandin E2 that primarily targets the PGE2 receptor. This compound exhibits significant biological activity by promoting cytoprotection in gastrointestinal cells and may inhibit gastrointestinal bleeding. Its applications in research include studies on inflammation, gastrointestinal health, and the pharmacological roles of prostaglandins in various biological processes.

5S(6R)-EET is a metabolite derived from arachidonic acid that acts as a potent inducer of prostaglandin E2 (PGE2) synthesis. This compound enhances intracellular calcium levels and inhibits sodium absorption, contributing to membrane depolarization. Its biological activity makes it a valuable tool for research focused on the regulatory roles of prostaglandins in various physiological processes.

16-Phenoxy tetranor Prostaglandin E2 is an analog of prostaglandin E2 (PGE2) that serves as a potent modulator of various biological processes. This compound exhibits significant biological activity by influencing the prostaglandin pathway, making it valuable for studying inflammatory responses and reproductive biology. Additionally, its role as a minor metabolite of sulprostone in human plasma provides insights into pharmacokinetics and metabolic pathways relevant to drug development and therapeutic applications.

Rebamipide-d4 is a deuterium-labeled derivative of Rebamipide, primarily targeting cyclooxygenase-2 (COX-2). This compound induces COX-2 expression and elevates prostaglandin E2 (PGE2) levels, thereby enhancing gastric mucosal defense mechanisms in a COX-2-dependent manner. Rebamipide-d4 is utilized in various research applications focused on gastric protection and the modulation of inflammatory responses.

5R(6S)-EET is a metabolite derived from arachidonic acid that functions as a PGE2 inducer. It activates the synthesis of endogenous prostaglandin E2, leading to inhibition of sodium absorption, an increase in intracellular calcium levels, and enhanced depolarization of transmembrane voltage. This compound displays stereoselectivity, exhibiting differential activity compared to its stereoisomer, 5S(6R)-EET. Its biological effects make it a valuable tool for研究 applications focusing on prostaglandin signaling and related pathways.

Ecraprost is a prodrug of prostaglandin E1, designed to enhance the bioavailability of PGE1 in therapeutic applications. It effectively inhibits platelet adhesion and macrophage infiltration, as well as the expression of proliferating cell nuclear antigen in injured arterial walls. Ecraprost is utilized in research related to cardiovascular health and vascular injury repair.

13,14-Dihydro-15-keto-PGE1 is a metabolite of prostaglandin E1 (PGE1) that exhibits inhibitory effects on platelet aggregation. It has been shown to inhibit ADP-induced aggregation in human isolated platelet-rich plasma with an IC50 value of 14.8 μg/mL. This compound is useful in research applications focusing on thrombotic disorders and the role of prostaglandins in platelet function.

13,14-Dihydro-15-keto-prostaglandin A2 is a derivative of 13,14-dihydro-15-keto PGE2, resulting from the non-enzymatic dehydration process. This compound is primarily involved in the metabolic pathway leading to the formation of bicyclo PGE2, which serves as a critical biomarker for PGE2 synthesis. Its significant role in prostaglandin metabolism makes it valuable for research in inflammation, pain, and various physiological processes associated with prostaglandins.

13,14-Dihydro PGE1 is a significant metabolite of Prostaglandin E1 (PGE1) that functions as a potent inhibitor of ADP-induced platelet aggregation, with an ID50 of 10.8 ng/mL in platelet-rich plasma. This compound is primarily utilized in research regarding cardiovascular health and platelet function. Its mechanism of action makes it valuable for studies focused on thrombotic disorders and the modulation of vascular responses.